Could a Pre-Surgery immune booster tame brain cancer?
NCT ID NCT07134842
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial is testing whether giving the immunotherapy drug ipilimumab before standard surgery and chemoradiation is safe and helpful for people with newly diagnosed glioblastoma, an aggressive brain cancer. Sixteen participants will receive up to two doses of ipilimumab before their usual treatment. The study aims to see if the drug can shrink or control the tumor and whether it causes serious side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ipilimumab (an immunotherapy drug)
What this could lead to
If it works, this could point toward a new way to treat glioblastoma by using the immune system before surgery to help control the disease.
What could go wrong
This is a very early, small phase I trial with only 16 people, so results may not apply to everyone. The drug may cause serious side effects, and it is not yet known if it improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
University College London Hospital
RECRUITINGLondon, Greater London, NW1 2PG, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact